NCT06932861 — Xinxin Zhang cancer vaccine trial
Exploratory Study of Personalized mRNA Vaccine in Patients With Refractory Rhabdomyosarcoma
Registry record
| Registry ID | NCT06932861 ↗ |
|---|---|
| Lead sponsor | Xinxin Zhang |
| Collaborators | — |
| Phase | Phase EARLY_PHASE1 |
| Status | Recruiting |
| Indication | Rhabdomyosarcoma |
| Enrollment | 5 participants (target) |
| Start date | 2025-10-13 |
| Primary completion | 2027-05-01 (est.) |
| Last registry update | 26 Oct 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT06932861), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
FAQ
What phase is NCT06932861?
NCT06932861 (Exploratory Study of Personalized mRNA Vaccine in Patients With Refractory Rhabdomyosarcoma) is registered on ClinicalTrials.gov as Phase EARLY_PHASE1, sponsored by Xinxin Zhang.
Is NCT06932861 recruiting?
As of the 2026-10-26 registry update, NCT06932861 is listed as "Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT06932861?
The lead sponsor is Xinxin Zhang.
What condition does NCT06932861 study?
The registered condition is Rhabdomyosarcoma. Primary completion is listed as 2027-05-01 (estimated).
Are results available for NCT06932861?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT06932861.
Back to the full neoantigen vaccine trial tracker — 106 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.